Day: November 3, 2025

PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that it is sponsoring the Dream Bowl 2026 and set a record date of November 14, 2025 for its shareholders to receive Dream Bowl 2026 Meme Coin, which will be distributed by DataVault AI. Scilex’s shareholders as of the record date of November 14, 2025 will receive one meme coin for each common share held. This digital collectible is intended to provide for immutable recognition of ownership and utility with ticketing information and embed exclusive details on invited athletes,...

Results exceed expectations Scottsdale, Ariz, Nov. 03, 2025 (GLOBE NEWSWIRE) — onsemi (the “Company”) (Nasdaq: ON) today announced its third quarter 2025 results with the following highlights:Revenue of $1,550.9 millionGAAP gross margin of 37.9% and non-GAAP gross margin of 38.0%GAAP operating margin of 17.0% and non-GAAP operating margin of 19.2%GAAP diluted earnings per share and non-GAAP diluted earnings per share of $0.63Cash from operations of $418.7 millionFree cash flow of $372.4 million grew 22% year-over-year to 24% of revenue Year-to-date share repurchases of $925 million, approximately 100% of free cash flow“Our third quarter results exceeded expectations, underscoring the strength of our strategy and the resilience of our business model. We’re seeing continued signs of stabilization across our core...

At 24 months, the target lesion primary patency (TLPP)1 was 41.7% At 24 months, the access circuit primary patency (ACPP)2 was 25.7%SOUTH JORDAN, Utah, Nov. 03, 2025 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced 24-month efficacy findings from the non-randomized AVG cohort of the WAVE trial. Results of the AVG cohort were presented during the Late-Breaking Clinical Trials session at the annual VIVA Foundation3 Venous Endovascular Interventional Strategies (VEINS) conference held in Las Vegas, NV. For the millions of patients diagnosed with advanced kidney disease, hemodialysis is a life-saving treatment that replaces the function of the kidneys. The administration of hemodialysis requires ongoing vascular access (access to blood vessels) that is commonly...

Aspocomp Group Plc, Stock Exchange Release, November 3, 2025 at 4:20 p.m. The new shares subscribed for in Aspocomp Group Plc’s directed share issue have been registered with the Trade Register. A total of 673,682 new shares subscribed for in Aspocomp’s Directed Share Issue have been registered with the Finnish Trade Register on October 31, 2025. After the registration of the new shares, the total number of shares in the company is 7,522,922 shares. The new shares will confer equal rights to the company’s existing shares from the date of registration. The new shares will be admitted to trading on Nasdaq Helsinki Ltd’s main list approximately from November 4, 2025 onwards. For further information, please contact Manu Skyttä, President and CEO,tel. +358 20 775 6860, manu.skytta(at)aspocomp.com. ASPOCOMP GROUP PLC Manu SkyttäPresident and...

SUMMIT data for bezuclastinib in NonAdvSM selected for two oral presentations which will describe its best-in-class potential Novel JAK2 V617F mutant-selective inhibitor announced as Cogent’s newest preclinical program; on-track for IND in 2026 WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced three presentations featuring bezuclastinib, including two oral presentations in NonAdvanced Systemic Mastocytosis (NonAdvSM), at the 67th Annual Meeting of the American Society of Hematology (ASH) being held December 6-9, 2025 in Orlando, FL. Cogent also announced today plans to describe its novel JAK2 V617F mutant-selective inhibitor as part of a poster presentation...

JAKKS x SEGA RenewalJAKKS Pacific, Inc. (NASDAQ: JAKK) today announced a partnership renewal with SEGA of America, Inc. (“SEGA®”) for the core the Sonic the Hedgehog Collection, maintaining JAKKS as the franchise’s lead global toy partner.SANTA MONICA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — JAKKS Pacific, Inc. (NASDAQ: JAKK) today announced a partnership renewal with SEGA of America, Inc. (“SEGA®”) for the core the Sonic the Hedgehog Collection, maintaining JAKKS as the franchise’s lead global toy partner. JAKKS will continue to design, manufacture, market, and sell Sonic the Hedgehog branded toy product lines worldwide. This multi-year partnership extends until 2029, allowing JAKKs to continue to design and produce action figures, playsets, vehicles, plush, collectibles, and other categories. The JAKKS line of Sonic...

SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced that updated clinical data from the NX-5948-301 Phase 1a/1b clinical trial have been selected for presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6 – 9, 2025, in Orlando, Florida. The data will be featured in two presentations: an oral presentation with new results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and a poster presentation with updated results in patients with Waldenström macroglobulinemia. In addition to these clinical presentations, Nurix...

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that two abstracts highlighting new clinical and translational data from the Phase 1/2 clinical trial of rondecabtagene autoleucel (ronde-cel, also known as LYL314) for the treatment of aggressive large B-cell lymphoma (LBCL) will be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. Ronde-cel is a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate, currently in pivotal development for the treatment of LBCL, that is designed to increase complete response rates and prolong the duration of response as compared to approved CD19‑targeted CAR T-cell...

LAS VEGAS, Nov. 03, 2025 (GLOBE NEWSWIRE) — Innovative Payment Solutions, Inc. (Trading Symbol ‘IPSI’ on OTCID), a provider of digital payment and fintech solutions, today announced the launch of its next-generation Crypto Payment Platform, designed to provide IPSI’s clients including those in online gaming, iGaming, and sportsbook sectors with seamless, compliant, and secure cryptocurrency payment capabilities. This new platform enables operators to accept and process digital assets such as Bitcoin, Ethereum, USDC, and other major cryptocurrencies in real time, while offering automatic conversion to fiat currencies and full integration with existing IPSI merchant services. Transforming Digital Commerce into Gaming and Beyond The IPSI Crypto Payment Platform bridges the gap between traditional and decentralized finance (DeFi) by...